AEDG PeptidevsLivagen

AEDG peptide (Ala-Glu-Asp-Gly) is the minimal active sequence of Epithalon and represents the core tetrapeptide responsible for its reported biological effects. According to the Khavinson peptide bioregulator theory, this short sequence has tissue-specific gene-regulatory activity, particularly targeting pineal gland cells and somatic cells capable of telomerase expression.

The primary reported mechanism is activation of telomerase, the ribonucleoprotein enzyme that maintains telomere length. AEDG is proposed to interact with regulatory elements in the hTERT gene promoter (encoding the catalytic subunit of telomerase), enhancing its transcription in somatic cells where hTERT is normally silenced or minimally expressed. Reactivation of telomerase allows cells to add TTAGGG telomeric repeats to chromosome ends, counteracting the progressive telomere shortening that occurs with each cell division and ultimately triggers replicative senescence. Cell culture studies from the Khavinson laboratory have reported that AEDG treatment extends the replicative lifespan of human fibroblasts and increases telomerase activity in peripheral blood mononuclear cells.

The second major reported mechanism involves regulation of pineal gland function. The pineal gland produces melatonin — the circadian rhythm hormone and potent antioxidant — and its function declines markedly with age (pineal calcification and reduced melatonin output). AEDG is proposed to modulate gene expression in pinealocytes, restoring melatonin synthesis toward more youthful levels. This would have downstream effects on circadian rhythm regulation, sleep quality, antioxidant defense, and immune function — all of which are modulated by melatonin. Additional reported effects include upregulation of antioxidant enzyme expression (SOD, catalase) and modulation of cell cycle regulatory genes. As with other Khavinson peptide bioregulators, the research base is predominantly from Russian institutions, and the proposed direct DNA-binding mechanism awaits independent validation.

Livagen is a short tripeptide (Lys-Glu-Asp) within the Khavinson bioregulator family — peptides hypothesised to regulate gene expression in tissue-specific ways by binding to gene promoter regions. Livagen is positioned as the liver-targeted member of this family, intended to modulate hepatocyte gene expression in ways that support liver regeneration and counteract age-related decline in hepatic function.

Proposed mechanisms include modulation of chromatin condensation states in hepatocyte and lymphocyte nuclei, upregulation of genes involved in hepatic detoxification pathways (cytochrome P450 enzymes, glutathione synthesis), and immunomodulatory effects in liver-resident immune cells. Russian research has reported livagen-induced increases in hepatocyte regeneration markers in animal models of liver injury and changes in lymphocyte chromatin organisation consistent with cellular rejuvenation.

As with all Khavinson tripeptides, the proposed action model is that livagen acts as a transient signalling molecule triggering longer-lasting changes in gene expression. Plasma exposure is brief (around 30 minutes) but downstream transcriptional effects are claimed to persist for weeks, justifying pulse-dosing protocols of 10-30 day courses repeated periodically. The evidence base for clinical efficacy is dominated by Russian gerontology research with limited independent Western replication, and clinical use outside Russia remains largely anecdotal. Livagen should not be used as a substitute for evidence-based liver disease management.